MCID: PSR019
MIFTS: 29

Psoriasis Susceptibility 13

Categories: Genetic diseases, Skin diseases

Aliases & Classifications for Psoriasis Susceptibility 13

MalaCards integrated aliases for Psoriasis Susceptibility 13:

Name: Psoriasis Susceptibility 13 54 29 13
Psoriasis Vulgaris 71 69
Psoriasis 71 69
Psoriasis 13 71
Psors13 71
Pv 71

Classifications:



External Ids:

OMIM 54 614070
MedGen 40 C3279754
MeSH 42 D011565

Summaries for Psoriasis Susceptibility 13

UniProtKB/Swiss-Prot : 71 Psoriasis 13: A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.

MalaCards based summary : Psoriasis Susceptibility 13, also known as psoriasis vulgaris, is related to psoriasis and psoriasis 14, pustular, and has symptoms including exanthema, pruritus and psoriasiform rash. An important gene associated with Psoriasis Susceptibility 13 is TRAF3IP2 (TRAF3 Interacting Protein 2). The drugs Cholecalciferol and Ergocalciferol have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and bone.

Description from OMIM: 614070

Related Diseases for Psoriasis Susceptibility 13

Diseases in the Psoriasis Susceptibility 1 family:

Psoriasis Susceptibility 13

Diseases related to Psoriasis Susceptibility 13 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 414)
id Related Disease Score Top Affiliating Genes
1 psoriasis 12.6
2 psoriasis 14, pustular 12.4
3 psoriasis susceptibility 1 12.4
4 guttate psoriasis 12.3
5 pustular psoriasis 12.2
6 psoriatic arthritis 12.1
7 psoriasis 2 12.1
8 psoriasis 15, pustular 12.0
9 psoriasis, protection against 12.0
10 pustulosis palmaris et plantaris 11.9
11 mental retardation and psoriasis 11.8
12 polycythemia vera, somatic 11.7
13 psoriatic juvenile idiopathic arthritis 11.5
14 tranebjaerg svejgaard syndrome 11.5
15 impetigo herpetiformis 11.4
16 pustulosis of palm and sole 11.2
17 arthritis 11.2
18 geographic tongue 11.1
19 parapsoriasis 11.1
20 subacute cutaneous lupus erythematosus 11.0
21 chronic recurrent multifocal osteomyelitis 11.0
22 singleton-merten syndrome 1 10.8
23 systemic onset juvenile idiopathic arthritis 10.8
24 singleton-merten syndrome 2 10.7
25 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.7
26 primary cutaneous amyloidosis 10.7
27 temporomandibular ankylosis 10.7
28 nail disorder, nonsyndromic congenital, 1 10.7
29 dermatitis 10.3
30 atopic dermatitis 10.2
31 skin disease 10.1
32 endotheliitis 10.1
33 bullous pemphigoid 10.0
34 alopecia 10.0
35 rheumatoid arthritis 10.0
36 hepatitis 9.9
37 crohn's disease 9.9
38 pemphigus 9.9
39 obesity 9.9
40 alopecia areata 9.9
41 pityriasis rubra pilaris 9.9
42 polycystic kidney disease 9.9
43 lichen planus 9.9
44 acne 9.9
45 contact dermatitis 9.9
46 porokeratosis 9.8
47 acute generalized exanthematous pustulosis 9.8
48 thyroiditis 9.8
49 lymphoma 9.8
50 spondylitis 9.8

Graphical network of the top 20 diseases related to Psoriasis Susceptibility 13:



Diseases related to Psoriasis Susceptibility 13

Symptoms & Phenotypes for Psoriasis Susceptibility 13

Clinical features from OMIM:

614070

UMLS symptoms related to Psoriasis Susceptibility 13:


exanthema, pruritus, psoriasiform rash

Drugs & Therapeutics for Psoriasis Susceptibility 13

Drugs for Psoriasis Susceptibility 13 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 12)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cholecalciferol Approved, Nutraceutical Phase 2 67-97-0 6221 10883523 5280795
2
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
3
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
4 Anti-Bacterial Agents Phase 2
5 Anti-Infective Agents Phase 2
6 Bone Density Conservation Agents Phase 2
7 Ergocalciferols Phase 2
8 Micronutrients Phase 2
9 Trace Elements Phase 2
10 Vitamins Phase 2
11 Calciferol Nutraceutical Phase 2
12 Vitamin D2 Nutraceutical Phase 2

Interventional clinical trials:


id Name Status NCT ID Phase Drugs
1 Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3 Completed NCT00789880 Phase 2 Vitamin D3;Placebo
2 NVC Test in Order to Assess Pathological Changes in Family Members of Patient Diagnosed With SSc Not yet recruiting NCT02795221

Search NIH Clinical Center for Psoriasis Susceptibility 13

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Psoriasis Susceptibility 13

Genetic tests related to Psoriasis Susceptibility 13:

id Genetic test Affiliating Genes
1 Psoriasis Susceptibility 13 29

Anatomical Context for Psoriasis Susceptibility 13

MalaCards organs/tissues related to Psoriasis Susceptibility 13:

39
Skin, Testes, Bone

Publications for Psoriasis Susceptibility 13

Variations for Psoriasis Susceptibility 13

UniProtKB/Swiss-Prot genetic disease variations for Psoriasis Susceptibility 13:

71
id Symbol AA change Variation ID SNP ID
1 TRAF3IP2 p.Asp19Asn VAR_047349 rs33980500

ClinVar genetic disease variations for Psoriasis Susceptibility 13:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 TRAF3IP2 NM_147686.3(TRAF3IP2): c.28G> A (p.Asp10Asn) single nucleotide variant risk factor rs33980500 GRCh37 Chromosome 6, 111913262: 111913262

Expression for Psoriasis Susceptibility 13

Search GEO for disease gene expression data for Psoriasis Susceptibility 13.

Pathways for Psoriasis Susceptibility 13

GO Terms for Psoriasis Susceptibility 13

Sources for Psoriasis Susceptibility 13

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....